Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: US Considers Half Dose Of Moderna Vaccine To Maximize Coverage

UK And US Look To Increase Vaccination Rate

Executive Summary

Operation Warp Speed leader wants to look at half dose of Moderna vaccine - but pledges that final decision will belong to the US FDA.

You may also be interested in...



Speculation Over Moderna Vaccine Deal With Tata, Wockhardt

Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing and/or marketing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.

UK Begins Controversial 12 Week Strategy With AZ and Pfizer Vaccines

Entering a new lockdown, the UK sees its plans to space out doses of the COVID-19 vaccines to 12 weeks as crucial to overcoming the pandemic.

Moderna Increases Minimum Supply Of Coronavirus Vaccine Doses For 2021

The company’s announcement that it would supply at least 600 million doses of mRNA-1273 came as US vaccination rates have fallen far short of expectations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel